MX2023001285A - Metodos para reducir la concentracion de glicoesfingolipidos en el tejido cerebral y metodos de tratamiento de enfermedades neurodegenerativas que implican los mismos. - Google Patents

Metodos para reducir la concentracion de glicoesfingolipidos en el tejido cerebral y metodos de tratamiento de enfermedades neurodegenerativas que implican los mismos.

Info

Publication number
MX2023001285A
MX2023001285A MX2023001285A MX2023001285A MX2023001285A MX 2023001285 A MX2023001285 A MX 2023001285A MX 2023001285 A MX2023001285 A MX 2023001285A MX 2023001285 A MX2023001285 A MX 2023001285A MX 2023001285 A MX2023001285 A MX 2023001285A
Authority
MX
Mexico
Prior art keywords
methods
brain tissue
treatment
same
neurodegenerative diseases
Prior art date
Application number
MX2023001285A
Other languages
English (en)
Spanish (es)
Inventor
Tanya Zaremba Fischer
Judith Peterschmitt
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2023001285A publication Critical patent/MX2023001285A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023001285A 2020-07-30 2021-07-30 Metodos para reducir la concentracion de glicoesfingolipidos en el tejido cerebral y metodos de tratamiento de enfermedades neurodegenerativas que implican los mismos. MX2023001285A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059047P 2020-07-30 2020-07-30
US202063131120P 2020-12-28 2020-12-28
PCT/IB2021/056971 WO2022024062A1 (en) 2020-07-30 2021-07-30 Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same

Publications (1)

Publication Number Publication Date
MX2023001285A true MX2023001285A (es) 2023-02-22

Family

ID=77265125

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001285A MX2023001285A (es) 2020-07-30 2021-07-30 Metodos para reducir la concentracion de glicoesfingolipidos en el tejido cerebral y metodos de tratamiento de enfermedades neurodegenerativas que implican los mismos.

Country Status (11)

Country Link
US (1) US20230372313A1 (cg-RX-API-DMAC7.html)
EP (1) EP4188381A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023535483A (cg-RX-API-DMAC7.html)
KR (1) KR20230047146A (cg-RX-API-DMAC7.html)
CN (1) CN116322679A (cg-RX-API-DMAC7.html)
AU (1) AU2021317180A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001362A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187086A1 (cg-RX-API-DMAC7.html)
IL (1) IL300096A (cg-RX-API-DMAC7.html)
MX (1) MX2023001285A (cg-RX-API-DMAC7.html)
WO (1) WO2022024062A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
KR20260021150A (ko) 2024-08-05 2026-02-13 충북대학교 산학협력단 Gba1 돌연변이 보인자의 dj-1 발현수준에 따른 파킨슨병의 위험도 예측 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
LT2685986T (lt) * 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
TW201642855A (zh) 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
US10617713B2 (en) * 2016-03-08 2020-04-14 Neurocentria, Inc. Methods of modifying neuronal function by changing intracellular magnesium levels
EP3452045A1 (en) * 2016-05-04 2019-03-13 Lysosomal Therapeutics Inc. Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof

Also Published As

Publication number Publication date
KR20230047146A (ko) 2023-04-06
JP2023535483A (ja) 2023-08-17
WO2022024062A1 (en) 2022-02-03
EP4188381A1 (en) 2023-06-07
CA3187086A1 (en) 2022-02-03
BR112023001362A2 (pt) 2023-02-14
CN116322679A (zh) 2023-06-23
AU2021317180A1 (en) 2023-03-23
US20230372313A1 (en) 2023-11-23
IL300096A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
BRPI0712322A2 (pt) compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
BRPI0608152A2 (pt) formulações para tratamento ocular
MX344308B (es) Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
MX2021011563A (es) Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
PH12021553223A1 (en) IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
PH12021553232A1 (en) 2h-indazole derivatives and their use in the treatment of disease
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
MX2024014117A (es) Sales de ácido piperidinil-metil-purina-amina-d-tartárico, formas cristalinas y su uso en el tratamiento de enfermedades y condiciones médicas
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
MX2023000610A (es) Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
WO2010018996A3 (ko) 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물
BR112023001362A2 (pt) Métodos para redução da concentração de glicoesfingolipídio no tecido cerebral e métodos de tratamento doenças neurodegenerativas envolvendo os mesmos
EP1628663A4 (en) METHOD FOR REDUCING AMYLOID DEPOSITION, AMYLOID NEUROTOXICITY AND MICROGLIOSIS
MY205498A (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
EA202193211A1 (ru) Лечение синуклеопатий
WO2023107552A3 (en) Purines and methods of their use
Rodda et al. Quality of life outcomes: ASCENDE-RT a multicenter randomized trial of radiation therapy for prostate cancer